Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment.
- Author:
Dal Yong KIM
1
;
Dae Ho LEE
;
Sun Joo JANG
;
Sang We KIM
;
Cheolwon SUH
;
Jung Shin LEE
Author Information
1. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. leedaeho@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Non-small-cell lung carcinoma;
Salvage therapy;
S-1;
Irinotecan;
Docetaxel
- MeSH:
Adenocarcinoma;
Camptothecin;
Carcinoma, Non-Small-Cell Lung;
Carcinoma, Squamous Cell;
Disease Progression;
Disulfiram;
Follow-Up Studies;
Glutamates;
Guanine;
Humans;
Male;
Prospective Studies;
Protein-Tyrosine Kinases;
Receptor, Epidermal Growth Factor;
Salvage Therapy;
Taxoids;
Pemetrexed
- From:Cancer Research and Treatment
2011;43(4):212-216
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was designed to evaluate the efficacy of a combination treatment of S-1 plus either irinotecan or docetaxel for advanced/metastatic non-small cell lung cancer (NSCLC) patients who have already failed 3 or more lines of treatment. MATERIALS AND METHODS: This was a prospective single center phase II study. The eligible patients received S-1 40 mg/m2 twice a day orally on days 1 though 14 combined with irinotecan 150 mg/m2on D1 only or docetaxel 35 mg/m2 on D1 and D8. The treatment was repeated every 3 weeks until disease progression, unacceptable toxicity, or patient refusal. The choice between the two regimens was made at the discretion of the treating physician. RESULTS: A total of 14 patients participated in the study. There were 3 patients with squamous cell carcinoma, 9 with adenocarcinoma, and 2 with NSCLC, NOS. Eight of the patients were male. There were 8 patients with an Eastern Cooperative Oncology Group (ECOG) of 1, and 6 patients with an ECOG of 2. All the patients had already been treated with platinum-based chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitor therapy. Out of the 14 patients, 10 received irinotecan and S-1 and the other 4 received docetaxel and S-1. Twelve patients had also received pemetrexed. Disappointingly, there were no response from 2 patients with a stable disease, and therefore, as per the protocol, we stopped the study early. With a median follow-up time of 49 months, the median survival time was 5.6 months (95% confidence interval, 4.3 to 6.9 months). CONCLUSION: S-1 containing doublets did not show activity in this population as a salvage treatment and further investigation cannot be recommended.
